BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia

Simply Wall St.08-15

BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors. The agreement gives BeOne access to four advanced-stage RAS(ON) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2659178401?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-15 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659178401","market":"nz","top_or_hot":-1,"title":"BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia","media":"Simply Wall St.","content":"<div>\n<p>BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors. The agreement gives BeOne access to four advanced-stage RAS(ON) ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-15 17:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors. The agreement gives BeOne access to four advanced-stage RAS(ON) ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0724618433.USD","symbol_name":"BGF NEW ENERGY \"A4\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors","article_id":"2659178401","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659178401","pubTimestamp":1786785946,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors.\nThe agreement gives BeOne access to four advanced-stage RAS(ON) inhibitors and includes joint clinical studies for combination cancer therapies.\nBeOne secures exclusive development and commercialization rights for these RAS(ON) assets in select Asian markets.\n\nThis type of oncology partnership highlights how drug developers and healthcare technology companies...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","MDCO":"麦迪逊医药","BK4605":"半导体精选","BK4512":"苹果概念","LU1861214812.USD":"Blackrock Future of Transport A2 USD","BK4526":"热门中概股","BK4141":"半导体产品","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","ONC":"百济神州","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","ON":"安森美半导体","BK4588":"碎股","LU0124384867.USD":"贝莱德新能源基金A2","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC"},"translate_title":"BeOne Medicines (ONC) 获得亚洲四种 RAS(ON) 抑制剂的权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ON":1.5,"ONC":1.5},"content_text":"BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors. The agreement gives BeOne access to four advanced-stage RAS(ON) inhibitors and includes joint clinical studies for combination cancer therapies. BeOne secures exclusive development and commercialization rights for these RAS(ON) assets in select Asian markets.  This type of oncology partnership highlights how drug developers and healthcare technology companies are working to reshape cancer treatment, and you can explore a broader set of related stocks through 44 healthcare AI stocks. NasdaqGS:ONC Earnings & Revenue Growth as at Aug 2026 BeOne Medicines is a US based oncology company that focuses on discovering and developing cancer treatments across the United States, China, Europe, and other markets. Access to additional RAS(ON) inhibitors directly supports its effort to broaden its treatment pipeline across multiple regions. Beyond the headline: 1 risk and 4 things going right for BeOne Medicines that every investor should see. AdvertisementHow does this deal fit BeOne Medicines' core strategy? The collaboration aligns with BeOne Medicines' focus on targeted oncology by pairing its own assets like BGB-58067 and BG-T187 with Revolution Medicines' four clinical RAS(ON) inhibitors. It gives BeOne more shots on goal in solid tumors while using its existing R&D and development infrastructure rather than building new programs from scratch. Does this change the BeOne Medicines Narrative investors have been using? The Narrative centers on BeOne turning a concentrated hematology driven story into a broader oncology platform backed by late stage trials and operational efficiency. Gaining access to multiple RAS(ON) inhibitors and leading a global registrational Phase 3 study supports that pipeline expansion theme, but it also adds execution and cost risk on top of already ambitious trial plans. If we take a look at the community Narrative for BeOne Medicines, we can see how this news fits into the bigger investment story. What should you watch next to see if this collaboration is working? The clearest early test will be how quickly BeOne moves the planned combination trials into the clinic and whether it starts the funded global registrational Phase 3 for a selected RAS(ON) inhibitor on the disclosed timetable. Concrete signs include trial initiations, patient enrollment updates and any interim efficacy or safety data shared through 2027. For the full picture including more risks and rewards, check out the complete BeOne Medicines analysis.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BeOne Medicines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659178401","isCrawlerRequest":true}